Klarna Group faces a dual challenge: surging commercial demand for its 'buy now, pay later' services and intensifying legal scrutiny over alleged IPO disclosure failures regarding credit risk. The stock's sharp decline shifts investor focus to upcoming quarterly results and credit quality metrics.
Nomura Holdings reported robust Q3 results, with its four main divisions hitting an 18.5-year profit high and ROE consistently exceeding targets. However, losses in its digital asset unit tempered overall gains, prompting the firm to announce a significant share repurchase program.
Northeast Bank's Q2 2026 results reveal a bank in transition: record loan growth and a promising new small business product are countered by rising charge-offs and a token dividend, leaving analysts divided on its investment narrative.
MarineMax's Q4 2025 results surpassed revenue forecasts, driven by robust premium boat sales, but profitability was hampered by industry-wide discounting and cautious consumer spending, leading to a wider-than-expected loss per share.
Levi Strauss & Co. (LEVI) posted stronger-than-expected full-year 2025 results, driven by organic growth and a strategic shift towards direct-to-consumer sales. Yet, with a muted stock performance year-to-date, investors are questioning if the iconic denim maker's transformation story is fully priced in.
Standex International Corporation reported robust fiscal second-quarter results, with revenue climbing to $221.32 million and net income reaching $2.12 million. The company raised its quarterly dividend by 6.3% and issued an upbeat forecast for the third quarter, reinforcing confidence in its strategic shift toward high-value engineered products.
Thermo Fisher Scientific reported a strong finish to 2025, with Q4 results exceeding expectations. While navigating currency volatility and tariffs, the life sciences giant highlighted growth in core biopharma sectors, strategic acquisitions like Clario, and a solid 2026 outlook.
In its Q4 2025 earnings call, SL Green Realty projected strong fundamentals for Manhattan's office market, citing robust leasing and AI-driven demand. Management reiterated ambitious 2026 financing and asset sale targets while reporting quarterly results that beat expectations.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
Parker-Hannifin posts record-breaking Q2 fiscal 2026 results, fueled by robust organic growth and margin expansion, particularly in aerospace. The industrial giant raises full-year guidance and details strategic progress on its planned acquisition of Filtration Group Corporation.
Jefferies raises price target on CS Disco following strong Q3 results fueled by its Cecilia AI platform, yet maintains a cautious 'Hold' rating as the company balances growth investments against profitability.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
KLA Corporation reports robust fiscal 2025 results driven by AI demand, but warns of supply constraints and geopolitical factors tempering near-term growth, with a significant acceleration projected for late 2026 and 2027.
KeyCorp's latest quarterly results beat expectations, fueled by higher net interest income and a return to full-year profitability. The regional bank also completed a $200 million share buyback and issued $750 million in new debt, while refreshing its board. Analysts suggest these moves fine-tune the bank's strategy rather than radically alter its investment narrative.
Shares of Southern Copper Corporation (SCCO) surged nearly 18% following the release of its blockbuster 2025 financial results, which featured record annual earnings and a dual cash-and-stock dividend. The performance underscores the miner's robust cash generation but also intensifies scrutiny over its lofty valuation and the execution risks of its massive project pipeline.
Mastercard reported robust Q4 and full-year 2025 results, driven by double-digit revenue growth and surging value-added services. Executives expressed confidence for 2026, highlighting strategic wins, investments in digital assets like stablecoins, and a focus on 'agentic commerce,' even as they plan a restructuring affecting 4% of staff.
Lazard Ltd. reported strong fourth-quarter and full-year 2025 results, driven by record financial advisory fees and a rebound in assets under management. Executives framed the performance as validation of the firm's long-term 'Lazard 2030' strategy, highlighting talent investments and a robust pipeline for future growth.
Despite reporting a near-doubling of annual net income and raising its 2026 outlook, electronics manufacturer Celestica saw its shares drop sharply Thursday as the market judged its stellar results to be already reflected in the price.
Dolby Laboratories (NYSE: DLB) kicked off fiscal 2026 with robust first-quarter results, exceeding its own revenue and earnings forecasts. The audio-visual technology leader credits strong deal timing and highlighted significant momentum in automotive, television, and mobile partnerships, including expanded ties with Qualcomm and major social media platforms.
